The radiosensitizer Onalespib increases complete remission in ¹⁷⁷Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts.

ABSTRACT:

Purpose

¹⁷⁷Lu-DOTATATE targeting the somatostatin receptor (SSTR) is utilized for treatment of neuroendocrine tumors (NETs). Onalespib, a heat shock protein 90 (HSP90) inhibitor, has demonstrated radiosensitizing properties and may thus enhance the effect of ¹⁷⁷Lu-DOTATATE. Consequently, the aim of this study was to assess the potential of Onalespib in combination with ¹⁷⁷Lu-DOTATATE in vivo and to examine the toxicity profiles of the treatments.

Methods

¹⁷⁷Lu-DOTATATE selectivity and distribution in NET xenografts were studied using biodistribution and autoradiography. Therapeutic effects of Onalespib in combination with ¹⁷⁷Lu-DOTATATE were studied in NET xenografts. Histological analyses were used to assess molecular e

SUBMITTER: Lundsten S 

PROVIDER: S-EPMC7075859 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature